Beyond building better brains: bridging the docosahexaenoic acid (DHA) gap of prematurity
- PMID: 25357095
- PMCID: PMC4281288
- DOI: 10.1038/jp.2014.195
Beyond building better brains: bridging the docosahexaenoic acid (DHA) gap of prematurity
Abstract
Long-chain polyunsaturated fatty acids (LCPUFA) including docosahexaenoic acid (DHA) are essential for normal vision and neurodevelopment. DHA accretion in utero occurs primarily in the last trimester of pregnancy to support rapid growth and brain development. Premature infants, born before this process is complete, are relatively deficient in this essential fatty acid. Very low birth weight (VLBW) infants remain deficient for a long period of time due to ineffective conversion from precursor fatty acids, lower fat stores and a limited nutritional provision of DHA after birth. In addition to long-term visual and neurodevelopmental risks, VLBW infants have significant morbidity and mortality from diseases specific to premature birth, including bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity. There is increasing evidence that DHA has protective benefits against these disease states. The aim of this article is to identify the unique needs of premature infants, review the current recommendations for LCPUFA provision in infants and discuss the caveats and innovative new ways to overcome the DHA deficiency through postnatal supplementation, with the long-term goal of improving morbidity and mortality in this at-risk population.
Conflict of interest statement
The authors declare no competing financial interests or conflicts of interest in relation to the work described. MB receives institutional and foundation support from the following: NIH – NICHD (1K08HD078504), NIH - COBRE P20 GM103620-01A1, Gerber Foundation Pediatric Nutrition Grant (PN12-005-1372-3069), Sanford Health Seed Grant Research Fund, Sanford Research.
Figures
References
-
- Agostoni C, Marangoni F, Stival G, Gatelli I, Pinto F, Rise P, et al. Whole blood fatty acid composition differs in term versus mildly preterm infants: small versus matched appropriate for gestational age. Pediatr Res. 2008;64(3):298–302. Epub 2008/05/07. - PubMed
-
- Lapillonne A, Groh-Wargo S, Gonzalez CH, Uauy R. Lipid needs of preterm infants: updated recommendations. The Journal of pediatrics. 2013;162(3 Suppl):S37–47. Epub 2013/03/06. - PubMed
-
- Clandinin MT, Van Aerde JE, Merkel KL, Harris CL, Springer MA, Hansen JW, et al. Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. The Journal of pediatrics. 2005;146(4):461–8. Epub 2005/04/07. - PubMed
-
- Henriksen C, Haugholt K, Lindgren M, Aurvag AK, Ronnestad A, Gronn M, et al. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics. 2008;121(6):1137–45. Epub 2008/06/04. - PubMed
-
- O’Connor DL, Hall R, Adamkin D, Auestad N, Castillo M, Connor WE, et al. Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics. 2001;108(2):359–71. Epub 2001/08/03. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
